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Group 2 innate lymphoid cells (ILC2) are implicated in allergic asthma as an early innate 
source of the type 2 cytokines IL-5 and IL-13. However, their induction in house dust 
mite (HDM)-mediated airway inflammation additionally requires T  cell activation. It is 
currently unknown whether phenotypic differences exist between ILC2s that are acti-
vated in a T cell-dependent or T cell-independent fashion. Here, we compared ILC2s 
in IL-33- and HDM-driven airway inflammation. Using flow cytometry, we found that 
surface expression levels of various markers frequently used to identify ILC2s were 
dependent on their mode of activation, highly variable over time, and differed between 
tissue compartments, including bronchoalveolar lavage (BAL) fluid, lung, draining 
lymph nodes, and spleen. Whereas in vivo IL-33-activated BAL fluid ILC2s exhibited an 
almost uniform CD25+CD127+T1/ST2+ICOS+KLRG1+ phenotype, at a comparable time 
point after HDM exposure BAL fluid ILC2s had a very heterogeneous surface marker 
phenotype. A major fraction of HDM-activated ILC2s were CD25lowCD127+T1/ST2low 
ICOSlowKLRG1low, but nevertheless had the capacity to produce large amounts of type 
2 cytokines. HDM-activated CD25low ILC2s in BAL fluid and lung rapidly reverted to 
CD25high ILC2s upon in vivo stimulation with IL-33. Genome-wide transcriptional profiling 
of BAL ILC2s revealed ~1,600 differentially expressed genes: HDM-stimulated ILC2s 
specifically expressed genes involved in the regulation of adaptive immunity through 
B and T  cell interactions, whereas IL-33-stimulated ILC2s expressed high levels of 
proliferation-related and cytokine genes. In both airway inflammation models ILC2s 
were present in the lung submucosa close to epithelial cells, as identified by confocal 
microscopy. In chronic HDM-driven airway inflammation ILC2s were also found inside 
organized cellular infiltrates near T cells. Collectively, our findings show that ILC2s are 
phenotypically more heterogeneous than previously thought, whereby their surface 
marker and gene expression profile are highly dynamic.
Keywords: allergy, asthma, il-33, group 2 innate lymphoid cell, house dust mite, mouse model
Abbreviations: BAL, bronchoalveolar lavage; BM, bone marrow; CLP, common lymphoid progenitor; HDM, house dust mite; 
iBALT, inducible bronchus-associated lymphoid tissue; ILC, innate lymphoid cell; ILC1, group 1 innate lymphoid cell; ILC2, 
group 2 innate lymphoid cell; ILC3, group 3 innate lymphoid cell; MLN, mediastinal lymph node; OVA, ovalbumin; PMA, 
phorbol 12-myristate 13-acetate; RNA-Seq, RNA sequencing; Th, T helper; Th2, T helper 2; Treg, T regulatory; YFP, yellow 
fluorescent protein.
2Li et al. ILC2 Phenotypes in Airway Inflammation
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1684
inTrODUcTiOn
The capability of group 2 innate lymphoid cells (ILC2) to secrete 
large amounts of IL-5 and IL-13 has led to the investigation of 
their role in the pathogenesis of allergic diseases in recent years 
(1, 2). ILCs are a family of effector lymphocytes that do not 
express antigen receptors. They are classified according to their 
transcription factor requirements and distinct cytokine secreting 
patterns that mirror the profiles of T helper subsets (3, 4). ILC2s 
were originally characterized as an IL-25- and IL-33-responsive 
cell population that provides a critical early source of type 2 
cytokines for the expulsion of parasitic worms (5–8). Like other 
ILC family members, ILC2s develop from the common lymphoid 
progenitors (CLP) and lack classic hematopoietic lineage markers 
and are thus defined as Lineage negative (9, 10). They express 
Thy-1 (CD90), c-Kit (CD117) and Sca-1 as well as a broad range of 
cytokine receptors, including IL-7Rα (CD127), IL-2Rα (CD25), 
IL-25R (IL-17RB), and IL-33R (T1/ST2), leading to frequent use 
of these markers to identify and isolate ILC2s (11–13).
When stimulated by epithelial cell-derived innate cytokines, 
such as IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), 
prostaglandin D2 from mast cells or cysteinyl leukotrienes secreted 
by activated hematopoietic cells, ILC2s rapidly expand and 
secrete large amounts of type 2 cytokines (1, 2, 14). Accordingly, 
intranasal administration of IL-25 or IL-33 induces eosinophilic 
airway inflammation and expansion of ILC2s, independently of B 
or T cells (15–17). Mouse models of allergic airway inflammation 
induced by papain and Alternaria have shown rapid release of 
IL-25 and IL-33 followed by robust ILC2 induction prior to T cell 
activation, suggesting an early sentinel function (16, 18–20). In 
contrast to these studies, exposure to other allergens such as 
Aspergillus and house dust mite (HDM) indicates a prominent 
role of T cells in the initiation of allergic inflammation (21, 22). 
We have previously shown that, in HDM-induced allergic inflam-
mation, ILC2 induction requires T  cell activation. Although 
accumulation of ILC2s in the bronchoalveolar lavage (BAL) 
fluid is independent of IL-33, cytokine production by ILC2s is 
markedly reduced in IL-33 knockout mice (22). Additionally, 
T  cell-derived IL-21 promotes type 2 immunity to HDM and 
blockade of CD28 signaling during HDM exposure represses 
airway hyperreactivity and lung inflammation (23, 24), further 
supporting that both IL-33 and T cells are necessary for full ILC2 
responses. Evidence for direct interactions between T cells and 
ILC2s includes the expression of MHC class II and co-stimulatory 
molecules such as CD86 and ICOS/ICOS-L by ILC2s (25–27). 
Taken together, these studies indicate the involvement of a 
complex array of signals and interactions for the activation of 
ILC2s in allergy. Importantly, ILC2s have mainly been studied 
in models in which they are strongly and rapidly activated in a 
T  cell-independent fashion, but the phenotypic characteristics 
of ILC2s induced in T cell-dependent inflammation, including 
HDM-mediated allergic airway inflammation models, is cur-
rently not clear. Studies using IL-5 and IL-13 reporter mice have 
shown that in unstimulated conditions or upon IL-33 stimulation 
pulmonary ILC2s are mainly localized in the lung submucosa 
close to epithelial cells in collagen-rich regions near blood vessels 
and airways (28, 29). However, ILC2 localization within a more 
physiological airway inflammation and their localization relative 
to Th2 cells remain unknown.
Plasticity of ILCs has first been reported in intestinal group 
3 innate lymphoid cells (ILC3), which downregulate RORγt 
expression and simultaneously upregulate T-bet to transform 
into a group 1 innate lymphoid cell (ILC1)-like phenotype 
depending on IL-12, IL-18, and IL-7 (30). Conversely, ILC1s 
can trans-differentiate into ILC3s in the presence of IL-1β 
and IL-23 (31). ILC2s are also able to upregulate T-bet under 
influence of IL-33 and IL-1β and can produce IFN-γ, whereby 
retention of IL-13 producing capabilities resulting in a hybrid 
ILC1/ILC2 phenotype has been reported (32–35). Heterogeneity 
and plasticity in relation to environmental signals have recently 
been substantiated by single-cell transcriptome analyses (36–38). 
Taken together, these publications demonstrate the importance 
of micro-environmental cues for the function of ILC2s. As a 
result, the expression of cytokines and cytokine receptors by 
ILC2s may depend on their manner of activation and may differ 
between tissues. Thus, we relied on transcription factor GATA3 
as a key ILC2 marker, which is central to ILC2 development and 
function and is constitutively expressed at high levels (39). We 
have previously reported dose-dependent effects of GATA3 both 
on ILC2 development from CLPs and on ILC2 function in allergic 
airway inflammation (40, 41). GATA3 additionally plays a major 
role as a master regulator of Th2 cell differentiation and drives the 
early development of other ILC subsets from the common ILC 
progenitor (42–44).
Although plasticity of ILC2 is studied in the context of 
their capacity to trans-differentiate into other types of ILCs, it 
remains unknown how the ILC2 phenotype is dependent on 
activation status, how it develops over time, what the differences 
are between various tissue compartments, and how stable or 
reversible the ILC2 phenotype is. In this report, we aimed to 
compare the dynamics and kinetics of the ILC2 phenotype in 
the context of T cell-independent and T cell-dependent airway 
inflammation using IL-33 and HDM, respectively. We employed 
a novel Gata3YFP/YFP mouse strain, named GATA3 IRES Reporter 
(GATIR), which allows for synchronous transcription of GATA3 
and yellow fluorescent protein (YFP) as separate proteins without 
affecting GATA3 protein levels or function (Tata Nageswara Rao 
and Hans Jörg Fehling, manuscript in preparation). These mice 
enabled us to characterize and compare the phenotype of ILC2s 
in detail in acute and chronic mouse models of airway inflam-
mation and to evaluate their localization in the lungs during an 
inflammatory response relative to other immune cells.
MaTerials anD MeThODs
Mice
Wild-type C57BL/6 mice were purchased from Envigo (United 
Kingdom). The GATIR mouse strain, in which an IRES-YFP 
sequence was inserted into the 3′ untranslated region of the 
Gata3 gene resulting in concomitant production of GATA3 and 
YFP protein, was on a C57BL/6 background (Tata Nageswara 
Rao and Hans Jörg Fehling, manuscript in preparation). Only 
homozygous GATIR knock-in mice were used for analysis. 
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Gata3+/− mice (C57BL/6), in which one of the Gata3 alleles is 
targeted by a lacZ reporter, have been described previously (45). 
Mice were ~8–16  weeks old at time of analysis. All animals 
were housed at the Erasmus MC Animal Center under specific 
pathogen-free conditions. All experiments were approved by the 
Erasmus MC Animal Ethics Committee.
induction of airway inflammation
For IL-33-induced airway inflammation, mice were anesthetized 
using isoflurane and treated three times intranasally or intratra-
cheally every other day with 0.5 µg IL-33 (BioLegend, USA) or 
PBS (GIBCO Life Technologies, USA) as described previously 
(17). Mice were sacrificed at the indicated time points after the 
final IL-33 administration.
For acute HDM-induced allergic airway inflammation, mice 
were anesthetized using isoflurane and sensitized by intranasal 
or intratracheal injection with 1 or 10 µg HDM extract (Greer, 
SC, USA) or PBS. After 7  days, animals were challenged daily 
on days 0–4 with 10 µg HDM intranasally or intratracheally and 
sacrificed at the indicated time points after the final treatment 
as described previously (46). For chronic HDM-induced allergic 
airway inflammation, mice were anesthetized using isoflurane 
and treated intranasally three times weekly for 5 weeks with 25 µg 
HDM or PBS and sacrificed at the indicated time points after the 
final treatment [adapted from Ref. (47)].
Flow cytometry
Single cell suspensions were prepared from lungs, lymph nodes, 
and spleens by mechanical disruption of the tissues without diges-
tive enzymes using a 100-µm cell strainer (BD Biosciences, USA) 
in PBS containing 0.5% bovine serum albumin and 5 mM EDTA 
(Sigma-Aldrich, USA). Bone marrow cells were extracted from 
the femur and BAL fluid was obtained by flushing the lungs three 
times with 1  mL PBS containing 0.5  mM EDTA. Intracellular 
cytokine production was measured upon stimulation of cells at 
37°C with phorbol 12-myristate 13-acetate (PMA) and ionomy-
cin (Sigma-Aldrich, USA), supplemented with GolgiStop (BD 
Biosciences, USA) for 4  h prior to staining. Flow cytometry 
surface and intracellular staining procedures have been described 
previously (17, 41). A comprehensive list of antibodies used 
for flow cytometry is presented in Table S1 in Supplementary 
Material. Lineage-negative cells were defined as cells not express-
ing CD3, CD4, CD5, CD8α, CD11b, CD11c, CD19, B220, NK1.1, 
FcεRIα, TER-119, and Gr-1. Data were acquired using a LSR II 
flow cytometer equipped with three lasers and FACSDiva (BD 
Biosciences, USA) and analyzed by FlowJo (Tree Star, Inc., USA).
ilc2 cell sorting and rna-seq
For FACS sorting, BAL fluid cells were stained with fluorescently 
labeled monoclonal antibodies. ILC2 fractions were sorted as 
Lineage−Sca-1+YFP+ cells using a FACSAria flow cytometer 
equipped with three lasers and FACSDiva software (Beckton 
Dickinson). Data analysis was performed with FlowJo software 
(Tree Star, Inc.).
RNA was extracted using the RNeasy Micro kit (Qiagen) 
according to the manufacturer’s instructions. Library preparation 
was performed using the Smart-seq2 methodology (48) and 
sequenced according to the Illumina TruSeq Rapid v2 protocol 
on an Illumina HiSeq2500 (single read mode, 51 bp read length). 
Reads were aligned to the mouse genome (mm10 build) using 
HISAT2 (49). Sample scaling and statistical analysis were 
performed using the R package DESeq2 (50) as implemented 
in HOMER (51); genes with >1 absolute log2-fold change and 
adjusted p  <  0.01 (Wald test) were considered differentially 
expressed. Standard Reads Per Kilobase Million (RPKM) values 
were used as an absolute measure of gene expression. Genes 
with average RPKM <2 were considered not expressed. Pathway 
analyses on differentially expressed genes were performed using 
Metascape1 (52).
confocal Microscopic imaging
Lungs from GATIR mice were inflated with OCT embedding 
medium containing 2% PFA (Thermo Fisher Scientific, USA) and 
snap frozen in liquid nitrogen to preserve morphology and YFP 
fluorescence. Lymph nodes were fixed in 2% PFA, placed in 30% 
sucrose in PBS overnight and embedded in OCT and stored at 
−80°C. 7-µm thick cryosections were cut at −20°C using a cryostat 
(Thermo Fisher Scientific) and stained at room temperature with 
primary antibodies for 1 h and secondary antibodies for 30 min. 
A comprehensive list of antibodies used for confocal microscopy 
is presented in Table S2 in Supplementary Material. Slides were 
stained with DAPI (Invitrogen, USA) for 5 min and sealed with 
Vectashield (Vector Laboratories, USA) and examined with an 
LSM 510 Meta confocal microscope equipped with a 405, 488, 
543, and 633 nm laser (Zeiss, Germany). Images were processed 
and analyzed in Fiji, an open source scientific image processing 
application based on ImageJ.2
statistical analysis
Statistical comparisons were performed by Mann–Whitney 
U tests and a p-value of <0.05 was considered statistically sig-
nificant. All analyses were performed using Prism (GraphPad 
Software, USA).
resUlTs
The gaTir Knock-in Does not affect 
gaTa3 expression levels
We aimed to make use of expression of the Gata3 gene as a 
central ILC2 marker that is independent of cell surface proteins 
on ILC2s. We have previously shown that GATA3 is critical for 
ILC2 development in a dose-dependent manner (40). Reduction 
of GATA3 levels as in Gata3+/− mice did not detectably affect 
splenic or thymic CD4+ and CD8+ T  cells in steady state 
(Figure S1A in Supplementary Material). However, a negative 
impact was observed on IL-33-induced ILC2 accumulation and 
cytokine production and the associated eosinophilia in the BAL 
fluid of mice (Figure S1B in Supplementary Material). Similar 
effects were found in an HDM-induced mouse model for airway 
1 http://metascape.org.
2 http://fiji.sc/.
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inflammation, whereby reduced GATA3 levels also affected 
CD4+ T cell accumulation and their cytokine content in the BAL 
fluid (Figure S1C in Supplementary Material). Despite normal 
development of CD4+ and CD8+ T  cells and normal in  vitro  
proliferation of naïve CD4+ T  cells following αCD3/αCD28-
mediated stimulation, Gata3+/− T cells showed a significant decline 
in type 2 cytokine production in vitro, indicating impaired Th2 
differentiation (Figures S1D,E in Supplementary Material).
It was, therefore, critical that the Gata3 reporter mice to be used 
for visualization and phenotypic characterization of ILC2s and 
Th2 cells had unaltered GATA3 expression. GATIR mice harbor 
an IRES-YFP sequence that was inserted into the 3′ untranslated 
region of the Gata3 gene, allowing for the production of YFP as 
a separate protein concomitant with Gata3 transcription (Tata 
Nageswara Rao and Hans Jörg Fehling, manuscript in prepara-
tion). We administered either IL-33 or HDM intranasally to 
GATIR mice to induce ILC2 activation and airway inflammation 
in a T  cell-independent and T  cell-dependent manner, respec-
tively (Figures 1A,B).
Group 2 innate lymphoid cells were defined by flow cytometry 
as Lineage− lymphocytes expressing YFP and Sca-1 (Figure 1C). 
Analysis of BAL fluid obtained 1  day after the final challenge 
showed that IL-33 triggered expansion of eosinophils, ILC2s, 
and to a lesser extent CD4+ T cells (Figure 1D). The YFP signals 
paralleled the expression of GATA3 protein, as detected by intra-
cellular flow cytometry using GATA3-specific antibodies, both 
within Lineage− and Lineage+ lymphocyte fractions (Figure 1E).
In HDM-mediated allergic airway inflammation B cells were 
also expanded, in addition to eosinophils, CD4+ T cells, and ILC2s 
(Figure 1F), and a similar correlation between GATA3 expres-
sion and YFP signals was found in both Lineage− and Lineage+ 
lymphocyte fractions (Figure  1G). Furthermore, the influx of 
eosinophils and ILC2s in BAL fluid after IL-33 administration 
did not differ between GATIR mice and wild-type controls. Upon 
IL-33 exposure, the mean fluorescence intensity (MFI) values 
of intracellular GATA3 in ILC2s were comparable between the 
two groups of mice in BAL fluid, lung, and mediastinal lymph 
node (MLN) (Figure S2A in Supplementary Material). Likewise, 
GATIR mice paralleled wild-type counterparts when exposed 
to HDM and no differences in the induction of eosinophils and 
CD4+ T  cells and GATA3 expression within Th2 cells were 
observed (Figure S2B in Supplementary Material). Taken together, 
these data demonstrate that YFP provides an accurate reflection 
of intracellular GATA3 expression, although a direct comparison 
between intracellular GATA3 protein and YFP levels could not 
be accomplished due to the loss of YFP signal during cell fixation 
required for GATA3 detection. We conclude that GATA3 protein 
levels and ILC2 and Th2 induction are not affected by the inserted 
IRES-YFP sequence, enabling us to use YFP expression in GATIR 
mice for the identification of ILC2s.
il-33 and hDM-stimulated ilc2s Display  
a Variable, Unstable, and heterogeneous 
surface Phenotype
Next, we compared the cell surface marker expression of ILC2s 
in steady state, in IL-33-mediated airway inflammation, as well as 
in HDM-induced allergic airway inflammation. Whereas IL-33 
induced a robust expansion of ILC2s in BAL fluid, lung, MLN, 
and spleen, HDM exposure resulted in a significant but more 
modest ILC2 response in BAL fluid, lung, and MLN but not in 
spleen (Figure 2A), as previously reported (17, 22).
Stimulation by IL-33 resulted in high surface expression of 
CD25, ICOS, KLRG1, and T1/ST2 on BAL fluid ILC2s, which are 
markers frequently used to define these cells (1, 2). In contrast, 
HDM-activated ILC2s in BAL fluid displayed large phenotypic 
heterogeneity and showed substantially reduced expression levels 
of CD25, ICOS, KLRG1, and T1/ST2, which were even lower than 
on ILC2s from naïve mice. ILC2s in lung and MLN showed a simi-
lar picture in that surface expression of CD25, ICOS, and KLRG1 
was lower on HDM-activated ILC2s than on IL-33-stimulated 
ILC2s. Cell surface expression of these three markers on spleen 
and bone marrow (BM) ILC2s were not different between mice 
with HDM-mediated inflammation and naïve mice, consistent 
with the expected localized effects of intranasal HDM exposure. 
T1/ST2 on ILC2s showed low expression in lung and spleen in 
both naïve mice and in mice with airway inflammation. On MLN 
and BM ILC2s the expression of T1/ST2 was upregulated fol-
lowing IL-33 but not following HDM exposure. IL-33-stimulated 
ILC2s in the BM were also high in KLRG1, typically expressed 
by inflammatory ILC2s in peripheral tissues, suggesting systemic 
ILC2 activation (2). In all compartments analyzed, the expression 
of CD117 and CD127 on ILC2s showed only minor differences 
between naïve and HDM-challenged mice. Whereas the effects 
of IL-33 on CD117 expression on ILC2s were modest, IL-33-
stimulated ILC2s in lung, MLN, and spleen featured a detectable 
downregulation of CD127 expression (Figure 2B).
Next, we further investigated whether the ILC2 phenotype 
alters over time after exposure to IL-33. GATIR mice were 
challenged with IL-33 and sacrificed at several time points 
after the final challenge. As expected, eosinophil counts gradu-
ally decreased, but ILC2 numbers appeared to peak on day 3 
(Figure  2C). ICOS and KLRG1 expression followed a similar 
pattern to eosinophils, while CD117 was upregulated at later 
time points. Remarkably, we found that while CD25 was initially 
highly expressed on IL-33-stimulated ILC2s, the expression was 
significantly decreased from day 3 after the final challenge and 
onward with similar trends in both BAL fluid and lung tissue 
(Figure  2D). Only minor changes were observed in T1/ST2 
expression and Thy1.2 (CD90.2) was mildly upregulated by day 
10 in a similar pattern as CD117 (Figure S3 in Supplementary 
Material). Furthermore, the percentage of ILC2s expressing 
proliferation marker Ki-67 significantly decreased at later time 
points, suggesting a decreased activation state (Figure S3 in 
Supplementary Material).
The characteristic downregulation of CD25 expression 
revealed a type of ILC2 phenotypic heterogeneity that to the best 
of our knowledge has not been described previously. Particularly 
in BAL fluid, but also in lung and MLN, IL-33-stimulated ILC2s 
showed a CD25highCD127low phenotype on day 1 after challenge 
while IL-33-exposed ILC2s on day 6 and HDM-activated ILC2s 
showed an inversed CD25lowCD127high phenotype (Figure  3A). 
When we specifically gated CD25low ILC2s present in BAL fluid 
and lung from mice with HDM-driven inflammation, we found 
FigUre 1 | Concomitant GATA3 and yellow fluorescent protein (YFP) expression in group 2 innate lymphoid cells (ILC2s) after IL-33 and house dust mite (HDM) 
stimulation. (a,B) Schemes for intranasal (a) IL-33 and (B) HDM treatment of GATA3 IRES Reporter mice for induction of acute airway inflammation. Mice  
were treated with PBS, IL-33, or HDM at indicated time points and analysis was performed 1 day after the final challenge. (c) Flow cytometric identification of 
Lineage−YFP+Sca-1+ ILC2s in bronchoalveolar lavage (BAL) fluid. (D,F) Quantification of eosinophils, CD4+ T cells, B cells, and ILC2s in the BAL fluid of IL-33  
and HDM-treated mice. Data are shown as mean + SEM of n = 3–5 mice per group of a single experiment and are representative of two independent experiments. 
*p ≤ 0.05 compared to PBS control unless otherwise indicated. (e,g) Analysis of intracellular GATA3 and YFP expression by flow cytometry in Lineage− and 
Lineage+ lymphocytes from BAL fluid of IL-33 and HDM-treated mice. Plots represent combined data using the concatenate option in FlowJo (n = 3–5), 
representative of two independent experiments.
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that these cells displayed low surface expression of ICOS, KLRG1, 
and T1/ST2 compared to gated CD25high ILC2s. However, both 
CD25high and CD25low ILC2s highly expressed CD90.2 on the 
cell surface (data not shown). Additionally, CD25high ILC2s 
present in HDM-driven and IL-33-driven inflammation showed 
differences as well, e.g., in surface CD127 expression in the lung 
FigUre 2 | Dynamics of phenotypic group 2 innate lymphoid cell (ILC2) heterogeneity in airway inflammation. (a) Quantification of ILC2s in bronchoalveolar lavage 
(BAL) fluid, lung, mediastinal lymph node (MLN), spleen, and bone marrow (BM) of GATA3 IRES Reporter mice treated with IL-33 and house dust mite (HDM).  
(B) Comparison of ILC2 phenotype in the indicated tissues derived from naïve (shaded), IL-33 (black), or HDM-treated (red) mice. Plots represent combined data 
using the concatenate option in FlowJo (n = 4–6), representative of two independent experiments. (c) Eosinophil and ILC numbers in BAL fluid of IL-33-treated mice 
at days 1, 3, 6, and 10 after the final challenge. (D) Quantification of BAL fluid and lung ILC2 surface markers expressed as mean fluorescence intensity (MFI) values. 
(a,c,D) Data are shown as mean + SEM of n = 4–6 mice per group of a single experiment and are representative of two independent experiments. *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001 compared to (a) naïve control or (c,D) D1 unless otherwise indicated.
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FigUre 3 | Expression of CD25 on group 2 innate lymphoid cells (ILC2s) is highly variable and time dependent. (a) Expression profiles of CD25 and CD127 on 
ILC2s from bronchoalveolar lavage (BAL) fluid, lung, and mediastinal lymph node (MLN) in PBS, IL-33 and house dust mite (HDM)-treated GATA3 IRES Reporter 
mice. (B) Flow cytometric analysis of CD25 expression on gated BAL fluid ILC2s in HDM-treated wild-type and Il33−/− mice, shown as histogram overlays, compared 
to control lineage marker positive cells. (c) Comparison of CD25 expression on gated BAL fluid ILC2s in PBS, IL-25, and IL-33-treated mice, shown as histogram 
overlays. (D) Expression profiles of CD25, CD127, T1/ST2, and Ki-67 over time on ILC2s from BAL fluid, lung, and MLN in HDM-treated mice. (a–D) Plots represent 
combined data using the concatenate option in FlowJo (n = 3–6), representative of two independent experiments.
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and in ICOS expression in BAL fluid and lung (Figure S4 in 
Supplementary Material).
Consistent with our previous finding that ILC2 induction in 
BAL fluid in HDM-driven allergic airway inflammation is IL-33 
independent (22), we noticed that the absence of IL-33 in HDM-
exposed Il33−/− mice did not change CD25 expression on ILC2s 
compared to wild-type control mice (Figure 3B). Stimulation of 
ILC2s with IL-25 also did not result in altered CD25 expression 
compared to IL-33-stimulated mice (Figure 3C). However, CD25 
expression did decrease further over time in HDM-challenged 
mice, in particular in the BAL fluid, although not as drasti-
cally as the kinetics seen in IL-33-challenged mice. Consistent 
with this finding, T1/ST2 and Ki-67 were also downregulated 
over time, while CD127 expression remained relatively stable 
(Figure  3D). We confirmed these findings in wild-type mice 
and found that, as expected, GATIR mice did not significantly 
FigUre 4 | Both CD25high and CD25low group 2 innate lymphoid cells (ILC2s) in house dust mite (HDM)-driven airway inflammation have the capacity to produce 
type 2 cytokines. (a) Flow cytometric analysis of IL-5, IL-13, and IL-17 production in bronchoalveolar lavage (BAL) fluid by CD25high and CD25low ILC2s of 
HDM-treated mice. Plots represent combined data using the concatenate option in FlowJo (n = 6), representative of two independent experiments. (B) Proportions 
of cytokine producing ILC2s in the BAL fluid after HDM stimulation, stratified by CD25 expression. (c) Comparison of proliferative capacity between CD25high  
and CD25low ILC2s in BAL fluid, lung, and mediastinal lymph node (MLN) of mice after HDM treatment as indicated by Ki-67 expression. (B,c) Data are shown  
as mean + SEM of n = 6 mice per group of a single experiment and are representative of two independent experiments. *p ≤ 0.05 compared to CD25high ILC2s 
unless otherwise indicated.
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differ from wild-type counterparts in both surface marker 
expression of ILC2s (Figure S5A in Supplementary Material) or 
cytokine production (Figure S5B in Supplementary Material) in 
BAL fluid, lung, or MLN.
Taken together, these findings show that in BAL fluid 
IL-33-stimulated ILC2s had an almost uniform CD25+CD127+ 
T1/ST2+ICOS+KLRG1+ phenotype, while HDM-induced ILC2s 
displayed a heterogeneous surface phenotype characterized by 
substantially lower levels of CD25, ICOS, and KLRG1. In both 
models of airway inflammation, ILC2s exhibited variable expres-
sion of many surface markers commonly used to identify ILC2s 
with substantial differences across tissues and dependent on the 
time of analysis, suggesting that the microenvironment and the 
stage of inflammation are important factors in determining ILC2 
phenotype.
Both cD25high and cD25low ilc2s have the 
capacity to Produce Type 2 cytokines
Next, we used intracellular flow cytometry following in  vitro 
stimulation with PMA and ionomycin for 4 h to determine the 
capacity of ILC2 to produce type 2 cytokines. Both CD25high and 
CD25low ILC2s present in BAL fluid from HDM-challenged mice 
had a similar capacity to produce IL-5, IL-13, and amphiregulin 
(Figures  4A,B). The proportions of the BAL fluid ILC2s that 
were IL-5+ and IL-13+ in HDM-driven inflammation were ~75 
and ~55%, respectively, which was significantly lower than the 
proportions observed upon IL-33 exposure (~95 and ~85%, 
respectively) (17). We found marginal levels of IL-4 production 
(data not shown), but IL-17 production was detectable in both 
CD25high and CD25low ILC2s, albeit at low levels (Figures 4A,B). 
In these experiments, we did not detect expression of IFN-γ. 
IL-17+ ILC2s were more clearly visible after IL-33 stimulation 
and decreased quite rapidly together with amphiregulin, in 
contrast to IL-5 and IL-13, which remained highly expressed 
(Figure S6A in Supplementary Material). Importantly, all IL-17-
producing ILC2s also secreted IL-5, hinting at functional plastic-
ity (Figure S6B in Supplementary Material). As analyzed by Ki-67 
expression, CD25low ILC2s were slightly more proliferative than 
CD25high ILC2s in BAL fluid, but not in lung or MLN (Figure 4C).
In summary, low surface expression of CD25 did not appear 
to impact the capacity of ILC2 to produce cytokines. In addition, 
a proportion of CD25high and CD25low ILC2s were able to secrete 
IL-5 and IL-17 simultaneously, suggesting a hybrid ILC2/ILC3 
function.
cD25low ilc2s in hDM-Treated Mice are 
reversed to a cD25high Phenotype upon 
subsequent stimulation with il-33
Recent publications describing the plasticity and heterogeneity 
of ILC2s (32–35) prompted us to investigate the reversibility of the 
FigUre 5 | CD25 expression on house dust mite (HDM)-stimulated group 2 innate lymphoid cells (ILC2s) is restored by acute IL-33 exposure. (a) Schemes for 
administration of HDM with and without subsequent IL-33 exposure in GATA3 IRES Reporter mice. (B) Quantification of bronchoalveolar lavage (BAL) fluid 
eosinophils, CD4+ T cells, B cells, and ILC2s in animals treated with PBS, HDM alone or in combination with IL-33. (c) Surface marker expression profile of BAL 
fluid ILC2s. (B,c) Data are shown as mean + SEM of n = 4 mice per group of a single experiment. *p ≤ 0.05 compared to PBS control unless otherwise indicated. 
(c) Plot represents combined data using the concatenate option in FlowJo (n = 4).
9
Li et al. ILC2 Phenotypes in Airway Inflammation
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1684
downregulation of CD25 on ILC2s as a result of HDM-induced 
allergic airway inflammation. GATIR mice were sensitized and 
challenged with HDM and subsequently treated with a single or 
double exposure to IL-33 (Figure 5A). Control mice were only 
treated with PBS. BAL fluid eosinophil, CD4+ T cell, and B cell 
counts were significantly elevated after HDM treatment and 
further exacerbated in a dose-dependent manner upon IL-33 
exposure. ILC2 numbers did not increase with a single IL-33 
treatment in HDM-exposed mice but required two consecutive 
IL-33 doses to expand (Figure 5B). However, CD25 expression 
on HDM-activated ILC2s was readily upregulated after a single 
IL-33 dose while numbers remained stable, indicating upregula-
tion of CD25 expression on existing cells as opposed to influx 
or generation of new CD25high ILC2s (Figure 5C). Other ILC2 
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activation markers, such as ICOS, KLRG1, and T1/ST2 were also 
upregulated, although less rapidly than CD25. Interestingly, the 
MFI values of CD117 and CD127 were initially decreased and 
returned to previously levels after a second IL-33 treatment, again 
highlighting the adaptability of ILC2 phenotype depending on 
the microenvironment (Figure 5C).
chronic hDM exposure Predominantly 
induces cD25low ilc2s, Which 
substantially contribute to Type 2 
cytokine Production in the airways
Because ILC2s have been implicated in the maintenance of 
chronic asthma (53), we next investigated accumulation and 
phenotype of ILC2s in GATIR mice chronically exposed to 
HDM for a period of 5  weeks (Figure  6A). We have recently 
shown that chronic HDM exposure induces allergic airway 
inflammation, in addition to the formation of inducible bron-
chus-associated lymphoid tissue (iBALT) and tissue remodeling 
in the lungs (54). At day 4 after the final challenge, we detected 
an eosinophilic infiltrate in the BAL fluid, indicative of active 
inflammation (Figure  6B). Compared with our acute HDM-
driven lung inflammation model, eosinophil numbers in BAL 
fluid were modest and the contribution of B cells was larger and 
in the same range as CD4+ T cells (Figure 6C). In comparison 
to PBS controls, the numbers of total ILC2s were significantly 
increased, of which the majority was CD25low (Figure 6D) and 
both CD25high and CD25low populations of ILC2s in the BAL fluid 
expressed IL-5 and IL-13 (Figure 6E). Compared with the acute 
HDM-driven inflammation model, a more sizeable contribution 
of ILC2s to the total number of cytokine producing cells was 
observed in chronic HDM airway inflammation exposure, of 
which the CD25low subset represented a larger proportion than 
the classic CD25high subset (Figure  6F). Next, we investigated 
whether the longevity of CD25high and CD25low ILC2s was differ-
ent in the resolution phase of chronic HDM-mediated allergic 
airway inflammation. We quantified CD25high and CD25low 
ILC2s at 3, 6, and 10 days after the last allergen challenge and 
found that total numbers of CD25low ILC2s appeared to be more 
persistent than CD25high ILC2s (Figure 6G).
Taken together, these findings show that ILC2s that are present 
in chronic HDM-driven allergic airway inflammation are promi-
nent producers of IL-5 and IL-13 and have a CD25low phenotype, 
particularly in the resolution phase of inflammation.
Transcriptome Profiling indicates That 
acutely activated ilc2s are Functionally 
Different from ilc2s in chronic airway 
inflammation
As outlined above, we found that the rapid and robust activation of 
ILC2s by IL-33 induces high levels of type 2 cytokine production 
by these cells (17) and an almost uniform CD25+CD127+T1/ST2+ 
ICOS+KLRG1+ phenotype. In contrast, CD25low ILC2s, exhibit-
ing lower surface expression of T1/ST2, ICOS, and KLRG1 and 
a more modest cytokine production capacity, dominated in our 
chronic HDM airway inflammation model.
To explore differences between acutely and chronically 
activated ILC2 populations in an unbiased and comprehensive 
fashion, we FACS-sorted BAL fluid ILC2s from GATIR mice 
1 day after the final challenge following IL-33 or chronic HDM 
exposure, respectively, and analyzed gene expression in these 
cell fractions by RNA-Seq. We identified a total number of 1,623 
differentially expressed genes, of which 915 were upregulated in 
IL-33-stimulated ILC2s and 708 in chronic HDM-stimulated 
ILC2s. Indeed, we found that the most significantly upregulated 
gene in IL-33-stimulated ILC2s was Il2ra encoding CD25 
(Figure  7A), confirming our flow cytometry data. Pathway 
analysis of these genes indicated that processes related to cell 
proliferation and division (Cenpe, Top2a, Ccnd2) are highly 
active after IL-33 stimulation (Figures 7A,B). In contrast, HDM-
exposed ILC2s showed a transcriptional signature associated 
with regulation of the immune system and immune cell activa-
tion, including “innate immune system” genes, such as Cd33, 
Ccr2, Ctsd, and Ctss (encoding Cathepsins D and S) and Csf2 
(encoding GM-CSF) (Figure  7C). Interestingly, chronic HDM 
exposure generated ILC2s with increased expression of genes 
implicated in the modulation of T cell activity (Flt3l, Icosl, Pdl1) 
and chemo-attraction of T and B cells (Ccl6, Cxcl10) (Figure 7D). 
Single nucleotide polymorphisms in Rgs2, and IRF5 activity have 
been associated with asthma (55, 56) and our data highlighted 
upregulated transcription of these genes in HDM-stimulated 
ILC2s (Figures 7A,D). Acutely, IL-33-activated ILC2s produced 
high levels of cytokine (Il5, Il13, Il9) and tissue-migratory 
chemokine receptor (Ccr4, Ccr7) genes, indicating an activated 
effector cell phenotype. Furthermore, mediators of innate signals 
were also prominent, including the TLR-signaling protein Myd88 
and IRF4, which is known to respond to IL-33 and TSLP (57). 
Surprisingly, IL-33-activated ILC2s showed low but detect-
able Tbx21 (encoding T-bet) transcripts, whereas we detected 
increased Rorc (encoding RORγt) levels in HDM-activated 
ILC2s, indicative of ILC2 plasticity toward group 1 and group 3 
ILCs, respectively (Figure 7D).
Taken together, these data suggest distinct roles of ILC2s 
dependent on the type and the duration of stimulus. While 
acutely activated ILC2s by IL-33 displayed a strong effector cell 
phenotype, chronically HDM-stimulated ILC2s appear to regu-
late and assist adaptive immunity.
ilc2s are situated Below the lung 
epithelium and inside cellular infiltrates 
induced by acute and chronic airway 
inflammation
The GATIR knock-in allowed us to visualize Th2 cells and 
ILC2s as YFP+ cells in  situ using confocal microscopy. Our 
RNA-Seq data suggest contrasting functions between rapidly 
and chronically activated ILC2s, thus we examined whether 
IL-33 and HDM-stimulated ILC2s differed in localization in the 
lungs. Exposure to IL-33, acute and chronic HDM according to 
the protocols described in Figures 1A,B and 6A generated lung 
inflammation outlined by perivascular and peribronchial cellular 
infiltrates and thickened alveolar walls compared to PBS treated 
mice (Figure 8A). Lung cryosections were counterstained with a 
FigUre 6 | Continued
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FigUre 7 | Gene expression signatures of group 2 innate lymphoid cells (ILC2s) are dependent on type and duration of stimulus. (a) Heat map and volcano plot  
of differentially expressed genes between IL-33 (n = 915) and chronic house dust mite (HDM)-stimulated (n = 708) ILC2s derived from bronchoalveolar lavage  
fluid 1 day after the final challenge. (B,c) Metascape pathway analysis of genes upregulated in (B) IL-33-activated and (c) chronic HDM-stimulated ILC2s.  
(D) Comparison of Reads Per Kilobase Millionvalues of selected differentially expressed genes in IL-33-activated (blue) and chronic HDM-stimulated (red) ILC2s.
FigUre 6 | Group 2 innate lymphoid cells (ILC2s) with CD25low phenotype are important cytokine producers in chronic house dust mite (HDM)-induced airway 
inflammation. (a) Scheme for intranasal HDM treatment of GATA3 IRES Reporter mice for induction of chronic allergic airway inflammation. (B) Quantification of 
eosinophils, CD4+ T cells, and B cells in the bronchoalveolar lavage (BAL) fluid of PBS and HDM-treated mice. (c) Relative contribution of CD4+ T cells, B cells,  
and ILC2s in the BAL fluid of acute and chronic HDM-treated mice. (D) Quantification of CD25high and CD25low ILC2s in the BAL fluid of PBS and HDM-treated mice. 
(e) Flow cytometric analysis and quantification of amphiregulin, IL-4, IL-5, and IL-13 production by CD4+ T cells, CD25low, and CD25high ILC2s in the BAL fluid of 
HDM-treated mice. Plots represent combined data using the concatenate option in FlowJo (n = 7), representative of two independent experiments. (F) Relative 
contribution of CD4+ T cells, CD25low, and CD25high ILC2s to the total number of amphiregulin (areg), IL-4, IL-5, and IL-13 producing cells in the BAL fluid of acute 
and chronic HDM-treated mice. (g) Numbers of CD25high and CD25low ILC2s in the BAL fluid after chronic HDM exposure at days 3, 6, and 10 after the final 
challenge. (B,D,e,g) Data are shown as mean + SEM of n = 5–7 mice per group of a single experiment and are representative of two independent experiments. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared to PBS control unless otherwise indicated.
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FigUre 8 | Continued
13
Li et al. ILC2 Phenotypes in Airway Inflammation
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1684
FigUre 8 | Continued  
Pulmonary group 2 innate lymphoid cells (ILC2s) are located within cellular infiltrates underneath the lung epithelium after IL-33, acute and chronic house dust mite 
(HDM) exposure. (a) Hematoxylin and eosin stained cryosections of lungs from PBS, IL-33, acute HDM and chronic HDM-treated GATA3 IRES Reporter (GATIR) 
mice. (B) Discrimination between ILC2s and Th2 cells by counterstain with CD3 and detection by confocal microscopy. (c) Lung cryosections from PBS, IL-33, and 
acute HDM-treated GATIR mice counterstained with CD3 and B220. (D) Lung and mediastinal lymph node (MLN) cryosections from chronic HDM-treated GATIR 
mice counterstained with CD3 and B220. In the confocal microscopy conditions, GATA3low cells (such as non-Th2 CD4+ T cells and basophils) are not YFP+. It is of 
note that in chronic HDM-driven airway inflammation, only ~10% of all CD4+ T cells in the lung consist of GATA3high Th2 cells (54). [A] indicates airway lumen. [V] 
indicates lumen of blood vessel. ILC2s are indicated by [arrows] and [*] indicates Th2 cells. [B] and [T] indicate B and T cell zones, respectively, separated by the 
dashed line. (a–D) Images are representative of two independent experiments.
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combination of CD3 and B220 to label T and B cells, respectively. 
YFP+ ILC2s were readily discriminated from YFP+ Th2 cells by 
the absence of positivity for CD3 counterstaining (Figure 8B).
Following IL-33 stimulation many CD3−YFP+ ILC2s were 
identified in cellular infiltrates directly underneath the lung 
epithelium, with T and B cells being largely absent (Figure 8C), 
corroborating previously reported data and our flow cytometric 
data (28, 29). In situ hybridization of GATA3 revealed signals 
in similar locations as YFP+ cells (Figure S7 in Supplementary 
Material), supporting that YFP signals reflect Gata3 transcription. 
In contrast, in acute HDM-induced airway inflammation T and 
B cells were present in higher numbers in the cellular infiltrates. 
Hereby, also CD3−YFP+ ILC2s were identified, although less 
abundantly present than after IL-33 stimulation (Figure 8C). The 
ILC2s were not present in clusters and we did not find evidence 
for frequent interaction with B or T cells.
Chronically HDM-treated GATIR mice displayed cellular 
infiltrates surrounding blood vessels and near the airways in 
similar locations as acute lung inflammation models. However, 
the infiltrates appeared denser in a hematoxylin and eosin stain 
(Figure  8A) and confocal microscopy revealed a well-defined 
organization within these infiltrates (Figure 8D). The infiltrates 
were composed of separated B and T  cell zones with striking 
similarity to iBALT structures found in influenza-infected lungs 
(58). CD3−YFP+ ILC2s were located at two distinct sites: in the 
submucosa close to epithelial cells, comparable to their location 
in IL-33-induced airway inflammation, as well as within the cel-
lular infiltrates close to the lung epithelium and in proximity of 
T cell clusters (Figure 8D). Interestingly, B cell areas were devoid 
of ILC2s suggesting preferential interaction of ILC2s with T cells. 
Neither in the submucosa nor within the cellular infiltrates did we 
find evidence for clustering or organization of ILC2s. Abundant 
numbers of Th2 cells, identified as CD3+YFP+ cells were found 
in the enlarged MLNs of chronically HDM-treated animals; 
CD3−YFP+ ILC2s were present near the border of the B and T cell 
zones (Figure 8D).
In summary, these data indicate that ILC2s accumulate in cel-
lular infiltrates underneath the lung epithelium after activation. 
In chronic HDM-driven inflammation, ILC2s are mainly located 
in the submucosa close to epithelial cells, but are also found inside 
organized cellular infiltrates in close proximity to both epithelial 
cells and T cells, but not B cells.
DiscUssiOn
In type 2 airway inflammation, ILC2s act as an early innate 
source of IL-5 and IL-13 when strong allergenic stimuli induce 
epithelial pro-inflammatory cytokines, including IL-33, that have 
the capacity to directly activate ILC2s independently of T cells 
(1, 2). However, because we previously found that in HDM-
mediated allergic airway inflammation ILC2s are activated by 
different T cell-dependent pathways and IL-33 is not required for 
the HDM-driven induction of ILC2s in the BAL fluid (22), we 
hypothesized that ILC2 phenotype, function, and localization in 
HDM- and IL-33-driven inflammation may be different.
When using GATIR mice in an acute HDM-driven airway 
inflammation model, we detected the induction of a much more 
heterogeneous ILC2 population in BAL fluid, lungs, and draining 
lymph nodes than upon robust IL-33-induced ILC2 activation. 
We found that a large proportion of the ILC2s expressed low 
levels of CD25, and that these CD25low cells were generally low for 
KLRG1, T1/ST2, and ICOS on the cell surface as well, although 
we observed compartmental differences (Figure  2B; Figure S4 
in Supplementary Material). Nevertheless, they displayed a 
type 2 cytokine profile that was similar to their classic CD25high 
counterparts. The CD25low ILC2s in HDM-treated mice could be 
reverted back to a CD25high phenotype by subsequent exposure 
to IL-33 and ILC2s lost high CD25 expression by day 3 after 
IL-33 treatment, demonstrating the adaptability of ILC2s. We 
also observed that the levels of cell surface marker expression are 
highly dynamic over time, as, e.g., shown by our analysis of CD25, 
CD117, ICOS, and KLRG1 surface expression at different time 
points after the last IL-33 exposure (Figure 2C).
Our IL-33 and HDM-treatment models are similar in terms 
of the activation period of ILC2s and the timing of the analysis: 
1 day after the last challenge (Figures 1A,B). In this context, it is 
of note that we have previously shown that in the HDM-driven 
model ILC2s are only activated in the allergen challenge phase 
when memory T  cells are present and not upon sensitization, 
even when a single dose of 100 µg of HDM is given (22). It is, 
therefore, conceivable that certain differences in ILC2 phenotype 
between IL-33- and HDM-stimulated ILC2s are related to changes 
in cell–cell interactions or cytokine environment, given that 
activation of ILC2s by IL-33 and HDM is T cell-independent and 
T cell-dependent, respectively (17, 22). Collectively, our findings 
show that the cell surface marker composition of ILC2s is highly 
dynamic: markers follow a specific kinetic pattern after activation 
and are dependent on the mechanisms by which these cells are 
activated, e.g., a requirement of T cells for their activation.
It is of note that quite some heterogeneity in the expression 
levels of cell surface molecules, including CD25, CD69, CD117, 
ICOS, and T1/ST2 on resident ILC2s in the lungs of naïve mice 
has been observed among published studies, which is likely due 
to differences in the experimental models and housing conditions 
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of the mice (59). On the other hand, our finding of, e.g., lower 
expression of T1/ST2 on lung ILC2s than on BAL ILC2s upon 
IL-33 or HDM-stimulation parallels reported observations in a 
Nippostrongylus brasiliensis infection model (60).
In chronic HDM-driven inflammation the CD25low ILC2s 
outnumbered CD25high ILC2s, remained elevated at least 10 days 
after the last antigen challenge in the resolution phase of inflam-
mation and produced substantial amounts of IL-5 and IL-13, 
thus contributing significantly to the total Th2 cytokine produc-
tion. Transcriptome comparisons of BAL fluid ILC2 populations 
from mice with acute IL-33-driven and chronic HDM-driven 
allergic airway inflammation revealed distinct gene expression 
profiles. Rapid and robust activation of ILC2s by IL-33 resulted in 
elevated transcript levels of genes involved in cellular proliferation 
and cytokine production. In contrast, in chronic HDM-mediated 
airway inflammation, ILC2s showed a transcriptional signature 
consistent with a capacity to modulate adaptive immunity by 
interacting with B and T cells. Visualization of ILC2s by confocal 
microscopy showed their submucosal accumulation upon IL-33 
exposure and their presence in cellular infiltrates upon HDM 
exposure. Chronic exposure to HDM was associated with the 
formation of organized cellular clusters with defined T and B cells 
zones where ILC2s were located in close proximity to epithelial 
cells and T cells but not B cells and did not appear to form clusters.
Development and function of ILC2s critically depends on 
high levels of unperturbed GATA3 expression (39–41). To 
facilitate identification of ILC2 populations, potentially differing 
with respect to the expression levels of commonly used ILC2-
associated surface markers, e.g., CD25 or KLRG1, we employed a 
novel strain of Gata3 reporter mice, termed GATIR, carrying an 
IRES-YFP reporter construct within the 3′ untranslated region of 
the endogenous Gata3 alleles (Tata Nageswara Rao and Hans Jörg 
Fehling, manuscript in preparation). Knock-in reporter mice are 
not without pitfalls and should not perturb the target gene expres-
sion itself. Therefore, we provided evidence that the presence of 
the GATIR reporter affected neither GATA3 protein levels (by 
intracellular flow cytometry with GATA3-specific antibodies), 
nor ILC2 surface marker profile or cytokine production. Although 
the IRES-driven reporter construct monitors gene expression at 
the transcript level, our intracellular flow cytometric analysis with 
GATA3-specific antibodies revealed a strong correlation between 
YFP signals and GATA3 protein in ILC2s and T cells.
Group 2 innate lymphoid cells were considered to be relatively 
homogeneous and less plastic compared to the other ILC family 
members. This point of view may have been triggered by the use 
of robust ILC2 induction models, such as administration of IL-25, 
IL-33, papain, and Alternaria to study these cells in the context of 
allergic asthma or dermatitis (15, 16, 18, 19, 61, 62). Our finding 
that in allergic airway inflammation ILC2s are a phenotypi-
cally and functionally more heterogeneous and phenotypically 
dynamic cell population than previously thought adds to the 
modified picture of ILC2s that includes their functional plasticity 
driven by IL-12, IL-18, or viral infection (32–35). In line with this 
notion, we detected simultaneous IL-5 and IL-17 production in 
HDM- and in particular IL-33-stimulated ILC2s and our results 
may support that ILC2s can upregulate T-bet or RORγt mRNA 
levels in a stimulus-specific manner. Phenotypical heterogeneity 
within the ILC2s induced in type 2 inflammation together with 
their functional plasticity allows ILC2s to adapt to changes in 
their microenvironment. Therefore, it is conceivable that these 
characteristics allow ILC2s to be involved in different human 
asthma endotypes, ranging from classic eosinophilic allergic 
airway inflammation to non-allergic airway hyperreactivity, as 
well as in infection-associated exacerbations.
By investigating the expression of several markers commonly 
used to define ILC2s, we identified a yet undescribed CD25low 
ILC2 surface phenotype. CD25 appeared to correlate well with the 
expression of T1/ST2 and in particular KLRG1, which is known as 
a marker for mature and inflammatory ILC2s (39, 63). This might 
suggest that the CD25low ILC2 population reflects an immature 
and non-inflammatory resident ILC2 population. However, in 
contrast to ILC2 progenitors in the BM, these CD25low ILC2s are 
able to produce effector cytokines and expand upon stimulation 
with HDM, which would argue against their immature nature 
(39, 64). In further support of this concept, we found that CD25low 
ILC2s (i) are typically present after IL-33 exposure when the total 
numbers of ILC2s in the BAL are highest (Figures  2C,D) and 
(ii) show prolonged cytokine production and contribute to the 
type 2 cytokine environment in our chronic HDM-driven allergic 
airway inflammation model. Indeed, the more pronounced role 
of ILC2s in chronic inflammation could be attributed to the 
acquisition of “memory-like” properties, as recently described 
(65). Such a memory phenotype allows experienced ILC2s to per-
sist for extended periods of time and respond more potently than 
naïve ILC2s. Cytokine signaling through the common gamma 
chain is required for the survival of ILC2s and it has been dem-
onstrated that IL-7 and in particular IL-2 synergistically augment 
ILC2 expansion in the presence of IL-33, which in turn promotes 
expression of CD25 in both adipose and lung tissue, thus forming 
a positive feedback loop by modulating sensitivity to IL-2 (6, 17, 
66–69). Accordingly, our study also demonstrates upregulation 
of CD25 after IL-33 exposure of HDM-experienced ILC2s. The 
source of IL-2 has earlier been proposed to be T  cell-derived, 
but recent data using IL-2 fate reporter mice has revealed that 
pulmonary ILC3 could be an innate producer of IL-2 (25, 69).
We found that high CD25 expression on the cell surface of 
IL-33-activated ILC2s was associated with a decrease in CD127 
expression and conversely that CD25high and CD25low HDM-
activated ILC2 showed persistent CD127 expression. This may 
imply that the CD25low ILC2s are more reliant on IL-7 for their 
survival and function. Therefore, it could be speculated that 
these ILC2s can partly escape cross-regulation by Tregs, which 
are reported to control ILC2 responses by competition for IL-2 
uptake (70). In a recent study, coculture of ILC2s with Tregs 
was shown to downregulate ICOS and CD25 expression (71). 
It is conceivable that CD25low ILC2s in HDM-mediated airway 
inflammation represent ILC2s that have interacted with Tregs 
in vivo, because IL-5 and IL-13 levels are substantially decreased 
in ILC2s cocultured in vitro with Tregs (71), and our expression 
analyses demonstrate that the CD25low ILC2s in HDM-driven 
inflammation have lower levels of cytokine transcripts than 
IL-33 activated ILC2s. However, it cannot be formally excluded 
that CD25low IlC2s are cells that just received an IL-2 stimulus 
leading to downregulation of the receptor. Based on our findings 
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in Il33−/− mice, we conclude that IL-33 is unlikely to play a key 
role in the regulation of CD25 in HDM-mediated allergic air-
way inflammation. The combination of signals that specifically 
triggers CD25 up- and downregulation on ILC2s remains to 
be elucidated. Although expression of CD25 has been reported 
in human ILC2s from skin biopsies, adipose tissue and in vitro 
cultured ILC2s derived from peripheral blood, it is unknown 
whether pulmonary ILC2s also express this marker and its role 
in disease pathology has not been elucidated (26, 35, 61, 62).
Mice that were chronically exposed to HDM displayed well-
organized and dense cellular clusters in the lungs reminiscent 
of iBALT structures seen after influenza infection (58). These 
structures harbored clear B and T  cell zones and we observed 
ILC2s in proximity to T cells and not B cells. Indeed, ILC2s can 
express molecules that allow them to interact with T cells such 
as MHC class II, CD86, and ICOS/ICOS-L in addition to their 
cytokine repertoire (25–27). In the lungs, their positioning would 
allow them to act as an intermediate messenger to shuttle signals 
from the epithelium to T cells. For example, activation of ILC2s 
by epithelial signals can help reinforce a Th2 phenotype through 
direct cell contact. Conversely, CD25high ILC2s may become more 
activated in the presence of T  cell-derived IL-2 and promote 
alternatively activated macrophages through IL-13, which in 
turn assist with repair of the epithelium and resolution of inflam-
mation. In the lymph nodes, we found that ILC2s were situated 
along the border of B and T cells, an optimal site to communicate 
with both cell types. In this context, our RNA-Seq data support 
the notion that ILC2s have the ability to interact with adaptive 
immune cells and revealed that HDM-stimulated ILC2s showed 
robust expression of FLT3L, ICOS-L, and PDL1, which would 
allow ILC2s to regulate B and T  cell functions. Additionally, 
ILC2-derived factors such as IL-5 can enhance Ig production (72).
In summary, in addition to the reported plasticity of ILC2 
toward other ILC subsets, we found that the ILC2 phenotype is 
highly dynamic. This phenotype is dependent on the mode of 
cellular activation, changes over time during stimulation, exhib-
its differences across tissues, and is reversible. In particular, we 
identified previously undescribed ILC2s with a GATA3+CD25low 
phenotype and a type 2 cytokine profile indistinguishable from 
their classic GATA3+CD25high counterparts. These CD25low ILC2s 
contributed substantially to type 2 cytokine production and are 
able to readily revert to a CD25high phenotype upon stimulation 
with IL-33. Although it cannot be excluded that CD25high and 
CD25low ILC2s represent separate subsets, the observed changes 
of CD25, KLRG1, ICOS, and T1/ST2 over time and differences 
between IL-33-activated and HDM-driven CD25high ILC2s point 
to a different activation status of a single ILC2 type. Our data 
suggest a more complex ILC2 phenotype than is currently appre-
ciated. Hereby, distinct functional capabilities of ILC2s, including 
responsiveness to IL-2, IL-33, or ICOS-L, are tissue-specific and 
dependent on the type and duration of the stimulus used. The 
observed phenotypic heterogeneity should, however, not hamper 
the identification and quantification of ILC2s as long as GATA3, 
which is invariably expressed by ILC2s, Sca-1, and CD90 are 
included in flow cytometric analysis strategies.
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